The Food and Drug Administration yesterday released a series of guidance documents intended to help manufacturers develop generic transdermal and topical delivery systems, products that deliver a drug through a patient’s skin. “Because of the inherent complexity of delivering a drug through a TDS, making generic copies of these complex drugs can be especially hard,” said FDA Commissioner Scott Gottlieb, M.D. “As a result, many branded TDS products like drug patches have not faced timely generic competition.” He said FDA has “made a new commitment to develop product specific guidance documents laying out how to develop a generic copy of a branded medicine for any currently marketed, branded complex medicine in an effort to advance a more efficient and effective framework for developing generic copies of complex drugs.” 

Related News Articles

Headline
The AHA, American Medical Association, American Society of Anesthesiologists, American Society of Health-System Pharmacists, and Association for Clinical…
Headline
Reps. Scott Peters, D-Calif., Eliot Engel, D-N.Y., Brett Guthrie, R-KY, Anna Eshoo, D-Calif., Richard Hudson, R-N.C., Michael McCaul, R-Texas, Kurt Schrader, D…
Headline
The Food and Drug Administration today released a proposed rule that would allow states and other non-federal government entities to establish programs to…
Headline
The Food and Drug Administration yesterday approved the first test to use next generation sequencing technology to detect HIV drug-resistance mutations in…
Headline
Pictured, from left to right: Peter Adamson, chair of the Children’s Oncology Group at the Children’s Hospital of Philadelphia; Brian Marden, chief…
Headline
The AHA, American Society of Anesthesiologists, American Society of Clinical Oncology, American Society of Health-System Pharmacists and Institute for Safe…